Sign in

Andrew Dusing

Research Analyst at Cleveland Research

Andrew Dusing is an Analyst and Partner at Cleveland Research Company, specializing in the animal health and payment technology sectors. He covers companies such as Fiserv, Global Payments, and leading firms in pharmaceuticals, diagnostics, distributors, and pet retail, providing market insights and sales performance analyses. Dusing began his career as an Associate on Cleveland Research's Healthcare team, having joined the firm in 2017 shortly after graduating from Miami University with degrees in Finance and Management in 2016. He brings industry expertise in life sciences and the pharmaceutical supply chain; however, specific public rankings, performance metrics, or securities licenses are not disclosed in available records.

Andrew Dusing's questions to Elanco Animal Health (ELAN) leadership

Question · Q3 2025

Andrew Dusing asked about Elanco's pricing strategy for 2026, specifically for the pet segment, noting that the industry has seen 3-4% price increases while Elanco's was closer to 1.5% this year. He inquired if Elanco could reach or exceed the normal industry range in 2026, considering innovation and the lapping of launch promotions. He also asked about Zenrelia's go-to-market strategy, particularly regarding distribution agreements, and the feedback from October following a competitor's decision to give its largest dermatology product to distribution at the end of September.

Answer

Bob VanHimbergen, CFO, stated that Elanco's pricing strategy is to align price with customer value. He emphasized that current year launches like Credelio Quattro and Zenrelia are excluded from the pricing calculation but will be included in 2026 pricing, which will impact the reported price growth. Jeff Simmons, President and CEO, affirmed Elanco's consistent and strong relationships with distribution partners, highlighting that Elanco offers a total portfolio, unlike competitors who may be more selective or change strategies year-to-year. He believes Elanco's consistent partnership approach has paid off and differentiated the company.

Ask follow-up questions

Question · Q3 2025

Andrew Dusing from Cleveland Research asked about Elanco's pet health pricing strategy for 2026, specifically if it could reach the industry's normal 3%-4% range or even exceed it, considering innovation and lapping launch promotions. He also asked for feedback on Zenrelia's go-to-market strategy, particularly regarding any changes or impacts from a competitor giving their largest dermatology product to distribution at the end of September.

Answer

CFO Bob VanHimbergen stated that Elanco's pricing strategy aligns with customer value, noting that current year launches like Quattro and Zenrelia are excluded from 2025 pricing calculations but will be included in 2026, potentially impacting the reported price growth. President and CEO Jeff Simmons emphasized Elanco's consistent and differentiated relationships with distribution partners, offering a total portfolio, which he believes has paid off and insulated them from competitors' selective distribution changes.

Ask follow-up questions

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%